Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707. According to the deal, Pfizer will pay $1.25 ...

Drugmakers Pfizer and Flynn Pharma have been ... so they were no longer subject to price regulations. Pfizer hiked the price of the drug between 780% and 1,600%, and also supplied the drug to ...

And although Pfizer's deal is with a China-based company, Pfizer said it plans to manufacture drug substance for SSGJ-7807 in Sanford, N.C., and make drug product in McPherson, Kan. As Evercore ...

Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China ... Citigroup raised 3SBio’s price target to HK$21.00 ($2.7) from HK$13.00 after the deal.

The agreement covers the development, manufacturing and commercialisation of the drug. Pfizer has been granted a global license, excluding China, as well as the option to obtain commercialisation ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the ...

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient. The State of Kansas has ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...